JosÃ© Antonio SacristÃ¡n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5889538/publications.pdf

Version: 2024-02-01

48	2,014	361045	253896
papers	citations	20	43
		h-index	g-index

67	67	67	2578
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allopurinol Hypersensitivity Syndrome: A Review. Annals of Pharmacotherapy, 1993, 27, 337-343.	0.9	311
2	Patient involvement in clinical research: why, when, and how. Patient Preference and Adherence, 2016, 10, 631.	0.8	244
3	Problems and solutions in calculating quality-adjusted life years (QALYs). Health and Quality of Life Outcomes, 2003, 1, 80.	1.0	228
4	Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Medical Informatics and Decision Making, 2013, 13, 6.	1.5	190
5	Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. Annals of Pharmacotherapy, 1993, 27, 1126-1133.	0.9	76
6	The Safety of Olanzapine Compared With Other Antipsychotic Drugs. Journal of Clinical Psychiatry, 2000, 61, 335-343.	1.1	63
7	Clinical research and medical care: towards effective and complete integration. BMC Medical Research Methodology, 2015, 15, 4.	1.4	49
8	Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study. Clinical Therapeutics, 2000, 22, 583-599.	1.1	47
9	No big data without small data: learning health care systems begin and end with the individual patient. Journal of Evaluation in Clinical Practice, 2015, 21, 1014-1017.	0.9	44
10	Use of Confidence Intervals and Sample Size Calculations in Health Economic Studies. Annals of Pharmacotherapy, 1995, 29, 719-725.	0.9	38
11	Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry, 2001, 1, 7.	1.1	35
12	A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics, 2011, 33, 1225-1245.	1.1	26
13	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273.	1.1	23
14	Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS ONE, 2020, 15, e0234705.	1.1	22
15	Drug Utilisation Studies as Tools in Health Economics. Pharmacoeconomics, 1994, 5, 299-312.	1.7	19
16	Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. European Neuropsychopharmacology, 2003, 13, 39-48.	0.3	17
17	Erythromycin-Induced Hypoacusis: 11 New Cases and Literature Review. Annals of Pharmacotherapy, 1993, 27, 950-955.	0.9	16
18	Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients. International Journal of Antimicrobial Agents, 2000, 15, 65-71.	1.1	16

#	Article	IF	Citations
19	Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Preference and Adherence, 2016, 10, 1.	0.8	16
20	Exploratory trials, confirmatory observations: A new reasoning model in the era of patient-centered medicine. BMC Medical Research Methodology, 2011, 11, 57.	1.4	13
21	Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en EspaÃ±a. Gaceta Sanitaria, 2004, 18, 50-57.	0.6	13
22	Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. EndocrinologÃa Y NutriciÃ³n (English Edition), 2011, 58, 331-340.	0.5	12
23	Pragmatic trials revisited: applicability is about individualization. Journal of Clinical Epidemiology, 2018, 99, 164-166.	2.4	12
24	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. Advances in Therapy, 2020, 37, 1479-1495.	1.3	12
25	Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. International Clinical Psychopharmacology, 2000, 15, 107-113.	0.9	11
26	Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain â€“ a cost-effectiveness comparison. BMC Psychiatry, 2014, 14, 298.	1.1	11
27	Some reflections on the use of inappropriate comparators in CEA. Cost Effectiveness and Resource Allocation, 2020, 18, 29.	0.6	11
28	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	3.8	10
29	Generalizability in Pragmatic Trials. JAMA - Journal of the American Medical Association, 2017, 317, 87.	3.8	10
30	SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. Journal of Affective Disorders, 1999, 52, 111-119.	2.0	8
31	Global index of safety (GIS). Journal of Clinical Epidemiology, 2001, 54, 1120-1125.	2.4	8
32	Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review. Perspectives in Psychiatric Care, 2012, 48, 198-207.	0.9	8
33	Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Advances in Therapy, 2016, 33, 2059-2068.	1.3	8
34	Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?. Value in Health, 2020, 23, 25-31.	0.1	7
35	How to assess the value of low-value care. BMC Health Services Research, 2020, 20, 1000.	0.9	7
36	Interferon Alfa-2a-Induced Impotence. DICP: the Annals of Pharmacotherapy, 1991, 25, 1397-1397.	0.2	6

#	Article	IF	Citations
37	Use of Salivary Caffeine Tests to Assess the Inducer Effect of a Drug on Hepatic Metabolism. Annals of Pharmacotherapy, 1996, 30, 736-739.	0.9	6
38	Health economics: the start of clinical freedom. BMC Health Services Research, 2010, 10, 183.	0.9	6
39	El mÃ©dico frente a la COVID-19: lecciones de una pandemia. Educacion Medica, 2020, 21, 265-271.	0.3	5
40	Individual point-of-care trials: a new approach to incorporate patientâ€™s preferences into personalized pragmatic clinical trials. Journal of Clinical Epidemiology, 2021, 130, 152-155.	2.4	5
41	On heterogeneity of treatment effects and clinical freedom. International Journal of Clinical Practice, 2015, 69, 6-8.	0.8	4
42	Improving Health Care Value by Considering Cost-effectiveness. JAMA - Journal of the American Medical Association, 2018, 320, 1287.	3.8	2
43	Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions. Rheumatology and Therapy, 2019, 6, 473-477.	1.1	2
44	The Negative Side of Cost-effectiveness Analysis-Reply. JAMA - Journal of the American Medical Association, 1997, 277, 1932.	3.8	1
45	Where is the person in precision medicine?. Journal of Evaluation in Clinical Practice, 2015, 21, 1022-1023.	0.9	1
46	Do new Cancer drugs offer good value for Money? the perspective of oncologists, payers, patients, and general Population. Clinical Therapeutics, 2015, 37, e18-e19.	1.1	0
47	Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?. Journal of Comparative Effectiveness Research, 2017, 6, 491-495.	0.6	0
48	"Dr. Sacristan and Colleagues Reply". Journal of Clinical Psychiatry, 2001, 62, 828-829.	1.1	0